Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Joe Riddle

Internal Medicine Norman, OK Medical Doctor

NPI 1336121573 CMS profile 60551

900 N Porter Ave, Suite 310, Norman, OK 73071

Open in the dashboard

General payments

$4,297

288 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Joe Riddle of Norman, OK is reported in the CMS Open Payments database as having received $4,297 across 288 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $13 1
2023 General $58 3
2022 General $802 47
2021 General $1,463 93
2020 General $745 49
2019 General $1,216 95

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joe Riddle
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Joe Riddle were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Joe Riddle Internal Medicine median Middle half National median
2019 $1,216 $159 $48–$570 $163
2020 $745 $119 $33–$402 $114
2021 $1,463 $135 $37–$521 $132
2022 $802 $141 $42–$496 $149
2023 $58 $149 $45–$519 $160
2024 $13 $154 $47–$537 $164
2025 $0 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Lilly USA, LLC $514 45 payments
  2. AstraZeneca Pharmaceuticals LP $417 28 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $413 25 payments
  4. Novo Nordisk Inc $326 25 payments
  5. AbbVie, Inc. $269 15 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $250 13 payments
  7. GlaxoSmithKline, LLC. $220 18 payments
  8. Amgen Inc. $213 15 payments
  9. Sanofi-Aventis U.S. LLC $196 12 payments
  10. Pfizer Inc. $177 12 payments
  11. Other $1,303 80 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $4,297 288 payments
Products named General payments · program years 2019–2024
  1. JARDIANCE Diabetes $374 22 payments
  2. TRULICITY $357 30 payments
  3. JARDIANCE Diabetes $336 29 payments
  4. FARXIGA $291 18 payments
  5. TRELEGY ELLIPTA $209 17 payments
  6. Ozempic $207 16 payments
  7. XARELTO $171 13 payments
  8. TRINTELLIX $163 8 payments
  9. VRAYLAR $159 10 payments
  10. MYRBETRIQ $154 7 payments
  11. Other $3,868 256 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

288 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Oklahoma

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record